Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-06-26 Sale | 2023-06-28 6:12 pm | Avalo Therapeutics Inc. | AVTX | ARMISTICE CAPITAL LLC Armistice Capital Master Fund Ltd. Boyd Steven 10% Owner | 3,683,542 | $0.58881 | $2,168,897 | 765,828 (Indirect Direct) | View |
| 2023-06-26 Purchase | 2023-06-27 4:10 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 1,608,000 | $0.64066 | $1,030,179 | 0 (Indirect Direct) | View |
| 2023-06-15 Purchase | 2023-06-20 4:04 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 8,160 | $3.8779 | $31,644 | 1,608,000 (Indirect Direct) | View |
| 2023-06-12 Purchase | 2023-06-14 4:14 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 16,899 | $3.7653 | $63,629 | 1,599,840 (Indirect Direct) | View |
| 2023-06-09 Purchase | 2023-06-13 4:41 pm | Avalo Therapeutics Inc. | AVTX | Sullivan Christopher Ryan Chief Financial Officer | 511 | $3.42 | $1,748 | 1,262 (Direct) | View |
| 2023-06-09 Purchase | 2023-06-13 4:39 pm | Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board | 4,000 | $3.42 | $13,680 | 13,220 (Direct) | View |
| 2023-06-07 Purchase | 2023-06-09 4:24 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 14,426 | $3.9124 | $56,440 | 1,582,941 (Indirect Direct) | View |
| 2023-05-31 Purchase | 2023-06-02 4:22 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 844 | $2.87 | $2,422 | 1,568,515 (Indirect Direct) | View |
| 2023-05-25 Purchase | 2023-05-30 4:27 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 2,671 | $2.7944 | $7,464 | 1,567,671 (Indirect Direct) | View |
| 2023-05-24 Purchase | 2023-05-24 4:15 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 9,000 | $2.9796 | $26,816 | 1,565,000 (Indirect Direct) | View |
| 2023-05-18 Purchase | 2023-05-22 4:30 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 26,621 | $3.3572 | $89,372 | 1,556,000 (Indirect Direct) | View |
| 2023-05-12 Purchase | 2023-05-16 5:23 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 4,379 | $2.5135 | $11,007 | 1,529,379 (Indirect Direct) | View |
| 2023-05-04 Purchase | 2023-05-08 4:10 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 25,000 | $2.7746 | $69,365 | 1,525,000 (Indirect Direct) | View |
| 2023-04-25 Purchase | 2023-04-27 4:07 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 7,500 | $2.9898 | $22,423 | 1,500,000 (Indirect Direct) | View |
| 2023-04-20 Purchase | 2023-04-24 4:32 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 17,500 | $3.0669 | $53,672 | 1,492,500 (Indirect Direct) | View |
| 2023-04-17 Purchase | 2023-04-18 4:08 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 25,000 | $2.955 | $73,874 | 1,475,000 (Indirect Direct) | View |
| 2023-04-10 Purchase | 2023-04-11 4:51 pm | Avalo Therapeutics Inc. | AVTX | Caissa Capital Management ltd. 10% Owner | 56,329 | $2.5301 | $142,516 | 1,450,000 (Indirect Direct) | View |
| 2023-02-07 Purchase | 2023-02-09 4:32 pm | Avalo Therapeutics Inc. | AVTX | ARMISTICE CAPITAL LLC Armistice Capital Master Fund Ltd. Boyd Steven 10% Owner | 450,000 | $0 | $0 | 4,899,370 (Indirect Direct) | View |
| 2022-12-09 Purchase | 2022-12-12 4:22 pm | Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board | 2,083 | $4.42 | $9,207 | 9,220 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-12-20 Option Award | 2023-12-21 4:05 pm | 2024-12-20 2033-12-20 | Avalo Therapeutics Inc. | AVTX | Persson Magnus Director | 3,334 | $0 | 3,334 (Direct) | View |
| 2023-12-20 Option Award | 2023-12-21 4:04 pm | 2024-12-20 2033-12-20 | Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director | 3,334 | $0 | 3,334 (Direct) | View |
| 2023-12-20 Option Award | 2023-12-21 4:03 pm | 2024-12-20 2033-12-20 | Avalo Therapeutics Inc. | AVTX | KAPLAN GILLA Director | 3,334 | $0 | 3,334 (Direct) | View |
| 2023-12-20 Option Award | 2023-12-21 4:01 pm | 2024-12-20 2033-12-20 | Avalo Therapeutics Inc. | AVTX | Chan Mitchell Director | 3,334 | $0 | 3,334 (Direct) | View |
| 2023-06-30 Option Award | 2023-07-05 4:07 pm | 2023-06-30 2033-06-30 | Avalo Therapeutics Inc. | AVTX | Persson Magnus Director | 28,308 | $0 | 28,308 (Direct) | View |
| 2023-06-30 Option Award | 2023-07-05 4:05 pm | 2023-06-30 2033-06-30 | Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director | 4,575 | $0 | 4,575 (Direct) | View |
| 2023-05-15 Option Award | 2023-05-17 07:44 am | 2024-05-15 2033-05-15 | Avalo Therapeutics Inc. | AVTX | Sullivan Christopher Ryan Chief Financial Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2023-05-15 Option Award | 2023-05-17 07:43 am | 2024-05-15 2033-05-15 | Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board | 100,000 | $0 | 100,000 (Direct) | View |
| 2023-03-31 Option Award | 2023-04-04 4:09 pm | 2023-03-31 2033-03-31 | Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director | 1,167 | $0 | 1,167 (Direct) | View |
| 2023-03-31 Option Award | 2023-04-04 4:07 pm | 2023-03-31 2033-03-31 | Avalo Therapeutics Inc. | AVTX | Persson Magnus Director | 7,222 | $0 | 7,222 (Direct) | View |
| 2023-02-13 Option Award | 2023-02-15 4:19 pm | N/A 2033-02-13 | Avalo Therapeutics Inc. | AVTX | Sullivan Christopher Ryan Chief Financial Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2023-02-13 Option Award | 2023-02-15 4:16 pm | N/A 2033-02-13 | Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board | 100,000 | $0 | 100,000 (Direct) | View |
| 2023-02-03 Acquisition | 2023-02-09 4:32 pm | N/A N/A | Avalo Therapeutics Inc. | AVTX | ARMISTICE CAPITAL LLC Armistice Capital Master Fund Ltd. Boyd Steven 10% Owner | 334 | $3.95 | 4,899,370 (Indirect) | View |
| 2022-12-30 Option Award | 2023-01-03 4:13 pm | 2022-12-30 2032-12-30 | Avalo Therapeutics Inc. | AVTX | Persson Magnus Director | 2,536 | $0 | 2,536 (Direct) | View |
| 2022-12-30 Option Award | 2023-01-03 4:11 pm | 2022-12-30 2032-12-30 | Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director | 410 | $0 | 410 (Direct) | View |
| 2022-10-05 Option Award | 2022-10-07 4:03 pm | 2023-10-05 2032-10-05 | Avalo Therapeutics Inc. | AVTX | NEIL GARRY ARTHUR CEO and Chairman of the Board | 75,000 | $0 | 75,000 (Direct) | View |
| 2022-10-05 Option Award | 2022-10-07 4:01 pm | 2023-10-05 2032-10-05 | Avalo Therapeutics Inc. | AVTX | Sullivan Christopher Ryan Chief Financial Officer | 25,000 | $0 | 25,000 (Direct) | View |
| 2022-09-30 Option Award | 2022-10-03 4:28 pm | 2022-09-30 2032-09-30 | Avalo Therapeutics Inc. | AVTX | Almenoff June Sherie Director | 605 | $0 | 605 (Direct) | View |
| 2022-09-30 Option Award | 2022-10-03 4:25 pm | 2022-09-30 2032-09-30 | Avalo Therapeutics Inc. | AVTX | KAPLAN GILLA Director | 3,080 | $0 | 3,080 (Direct) | View |